FDA issued a warning letter to Harbin Jixianglong Biotech after inspectors found compliance issues tied to semaglutide API shipments under the agency’s “green list” import controls. The company was reportedly authorized to ship GLP-1 APIs from a compliant facility, but FDA said Jixianglong allegedly repackaged and relabeled externally procured semaglutide. In the agency’s account, inspectors identified potential attempts to circumvent safeguards by identifying the API as manufactured at the approved site when the semaglutide originated from a facility not on the green list. FDA cited missing documentation for repackaging and labeling and noted that initial responses did not fully address concerns about batches already in the U.S. The enforcement action underscores how supply-chain compliance is becoming a central risk area for GLP-1 availability as demand continues to pressure manufacturing and sourcing networks.